Randomized Study of Ibrutinib versus Ibrutinib Plus Rituximab (I Versus Ir) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
MD Anderson Study Status
You are being asked to take part in this study because you have chronic lymphocytic leukemia (CLL) with a chromosomal abnormality (17p/TP53 deletion) or CLL that has come back after treatment. The goal of this clinical research study is to learn if the combination of ibrutinib and rituximab can help to control CLL better than ibrutinib alone. The safety of these treatments will be also studied.
Information and next steps
For general questions about clinical trials: